InMode Ltd. (NASDAQ:INMD) Shares Purchased by Cwm LLC

Cwm LLC increased its stake in shares of InMode Ltd. (NASDAQ:INMD) by 38.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 2,454 shares of the healthcare company’s stock after acquiring an additional 680 shares during the period. Cwm LLC’s holdings in InMode were worth $55,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in INMD. Janney Montgomery Scott LLC boosted its stake in shares of InMode by 1.5% during the 3rd quarter. Janney Montgomery Scott LLC now owns 40,278 shares of the healthcare company’s stock worth $1,227,000 after acquiring an additional 601 shares in the last quarter. Los Angeles Capital Management LLC boosted its position in InMode by 1.9% during the third quarter. Los Angeles Capital Management LLC now owns 33,916 shares of the healthcare company’s stock worth $1,033,000 after purchasing an additional 640 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in InMode by 2.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 35,643 shares of the healthcare company’s stock valued at $793,000 after purchasing an additional 701 shares during the last quarter. Citigroup Inc. increased its position in shares of InMode by 1.6% in the third quarter. Citigroup Inc. now owns 63,332 shares of the healthcare company’s stock valued at $1,929,000 after buying an additional 975 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its stake in shares of InMode by 1.9% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 56,925 shares of the healthcare company’s stock worth $1,733,000 after buying an additional 1,081 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

InMode Price Performance

Shares of NASDAQ INMD opened at $18.30 on Thursday. The company has a 50-day simple moving average of $19.72 and a 200-day simple moving average of $21.31. The company has a market cap of $1.54 billion, a PE ratio of 8.67 and a beta of 2.20. InMode Ltd. has a 12 month low of $16.72 and a 12 month high of $48.25.

InMode (NASDAQ:INMD) last released its earnings results on Tuesday, February 13th. The healthcare company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.66 by $0.05. InMode had a net margin of 38.84% and a return on equity of 26.15%. The firm had revenue of $126.80 million during the quarter, compared to analysts’ expectations of $124.77 million. During the same period in the previous year, the company earned $0.69 EPS. InMode’s revenue for the quarter was down 5.1% on a year-over-year basis. On average, analysts anticipate that InMode Ltd. will post 2.04 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on INMD. UBS Group increased their price objective on shares of InMode from $24.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, February 14th. Barclays lowered their price target on shares of InMode from $34.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, April 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a research note on Friday, May 3rd. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, InMode currently has a consensus rating of “Hold” and an average target price of $32.80.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.